Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Myovant Sciences acquired for $2.9 BLN on second offer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 24, 2022 11:24am

121 Views

Post# 35043673

RE:Myovant Sciences acquired for $2.9 BLN on second offer

Notwithstanding Myovant Sciences GnRH receptor antagonist, the progress of, and investment in, MVT-602 had stalled. In its 2021-22 financial year, Myovant recorded $318,000 in R&D costs specific to the candidate, down from $4.9 million in 2018-19. No mention of the molecule was made in its statement to disclose the Myovant merger.

<< Previous

Bullboard Posts

Next >>

Junior helium miner will explore record discovery in Q4